Abstract

First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Recent major advances in cardiovascular pharmacotherapy.
Natália António ... Andreia Cunha
European journal of clinical pharmacology | VOL. 74
Natália António, et. al.Natália António ... Andreia Cunha
27 Mar 2018
Recent advances in therapeutic targeting of inflammation in atherosclerosis
Ulf Hedin ... Ljubica Perisic Matic
Journal of Vascular Surgery | VOL. 69
Ulf Hedin, et. al.Ulf Hedin ... Ljubica Perisic Matic
24 Dec 2018
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis.
Julian D Gillmore ... Marianna Fontana
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | VOL. 37
Julian D Gillmore, et. al.Julian D Gillmore ... Marianna Fontana
16 Feb 2023
Gene-Editing Technology Accelerates Cardiovascular Research: Clinical Applications Being Explored.
Bridget M Kuehn
Circulation | VOL. 137
Bridget M KuehnBridget M Kuehn
27 Feb 2018
View more papers

More From: European heart journal. Cardiovascular pharmacotherapy

Paper Title
Journal
Date
Author
Re: Shahim et al., 2024 cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
Arina A Tamborska ... Tobias Kurth
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Arina A Tamborska, et. al.Arina A Tamborska ... Tobias Kurth
28 May 2024
Long-term Effects of Phosphodiesterase-5 Inhibitors on Cardiovascular Outcomes and Death: A Systematic Review and Meta-analysis.
Stergios Soulaidopoulos ... Charalambos Vlachopoulos
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Stergios Soulaidopoulos, et. al.Stergios Soulaidopoulos ... Charalambos Vlachopoulos
22 May 2024
Utilizing genetics and proteomics to assess the role of antihypertensive drugs in human longevity and the underlying pathways: a Mendelian randomization study.
Bohan Fan ... Jie V Zhao
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Bohan Fan, et. al.Bohan Fan ... Jie V Zhao
20 May 2024
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension.
Juan Tamargo
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Juan TamargoJuan Tamargo
16 May 2024
View more papers